title: [Prophylaxis of cytomegalovirus infection in renal transplantation].
abstract: Cytomegalovirus (CMV) infection remains a major problem in renal transplant recipients. CMV produces not only febrile syndromes and/or visceral disease but also contributes to the development of acute rejection and chronic graft failure. Valganciclovir prophylaxis has represented a major advance in controlling this infection, but late CMV infection after prophylaxis can occur, especially when universal prophylaxis is used. The use of valganciclovir prophylaxis for 200 days is more effective than prophylaxis for 100 days but does not completely prevent this problem. Prophylaxis based on the detection of CMV viremia (early prophylaxis or preemptive therapy) may prevent the development of delayed CMV disease, but has the disadvantage of requiring more intensive monitoring of viremia and does not prevent the development of viremia and its potential consequences in the long term. This article reviews current recommendations for prophylaxis of CMV disease in renal transplantation.
authors.affiliation: Unidad de Enfermedades Infecciosas, Hospital Universitario 12 de Octubre, Madrid, España. jaguadog@medynet.com
authors.forename: José María
authors.initials: JM
authors.lastname: Aguado
authors.forename: Salvador
authors.initials: S
authors.lastname: Gil Vernet
mesh_terms: D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D006801:Humans; D016030:Kidney Transplantation; D011183:Postoperative Complications / Q000517:prevention & control*; D017410:Practice Guidelines as Topic